|Other Titles:||Treatment for Infection in the Urinary Tract with Oleandomycin|
|Authors:||稲田, 務 |
|Author's alias:||INADA, Tsutomu|
|Abstract:||Oleandomycin, one of the new antibiotics discover e d in the Pfizer Laboratories, was used for both research and clinical studies. Results : 1) As sh o wn in table 4, Oleandomycin revealed an activity against strains of micrococcus pyogenes var. aureus 209P which had become resistant in the laboratory to Penicillin, to Streptomycin, to Chloramphenicol, to Oxytetracycline, to Tetracycline or to Erythromycin. 2) As shown in table 5, Oleandomycin revealed no cross resistance with Penicillin, Streptomycin, Chlortetracycline and Oxytetracycline. 3) As demonstrated in figure 1, the concentration of Oleandomycin in serum followed by oral administration to healthy adults on a dosage of 500 mg presented its peak two or three hours after the administration and its activity was demonstrated at the end of six hours yet. 4) As shown in table 6, Oleandomycin was successfully used in the treatment for urinary tract infections, including 8 cases with acute gonococcal urethritis , 5 cases with non-gonococcal urethritis, 3 cases with cystitis, 3 cases with pyelitis and 1 case with pyelonephritis. No side-reaction was recognized against this autibiotic compound , so far as this study was concerned. 01eandomycin(P, A.105, Matromycin(R))|
|Appears in Collections:||Vol.4 No.1|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.